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Background: Patients with rheumatoid arthritis (RA) have increased cardiovascular (CV) and mortality risk. Patients
with RA are also frequently prescribed glucocorticoids (GCs) which have been associated with increased risk of
mortality. In addition, for patients who have concomitant diabetes mellitus (DM), GCs are known to worsen
glycaemic control and hence may further increase CV and mortality risk. This study aimed to understand the
relationship between GCs, DM and mortality in patients with RA.
Methods: This was a retrospective cohort study of patients with incident RA identified from UK primary care electronic
medical records. Patients with linkage to Office for National Statistics (ONS) for mortality data (N = 9085) were included.
DM was identified through Read codes, prescriptions and blood tests, and GC use was identified through prescriptions.
Mortality rate ratios (RR) and rate differences (RD) were calculated across the different exposure groups. Cox proportional
hazards regression models were used to estimate interaction on the multiplicative and additive scales.
Results: In those without DM GC use had a 4.4-fold increased all-cause mortality RR (95% confidence interval (CI): 3.77
to 5.07) compared to non-use, whilst those with DM had a lower RR for GC use (2.99 (95% CI: 2.32, 3.87)). However,
those with DM had a higher RD associated with GC use because of their higher baseline risk. In those with DM, GC use
was associated with an additional 44.9 deaths/1000 person-years (pyrs) (95% CI: 32.9 to 56.8) compared to non-use,
while in those without DM GC use was associated with an additional 34.4 deaths/1000 pyrs (95% CI: 30.1 to 38.7)
compared to non-use, while in those without DM GC use was associated with an additional 36.2 deaths/1000 pyrs
(95% CI: 31.6 to 40.8). A similar pattern was seen for CV mortality. The adjusted Cox proportional hazards model
showed no evidence of multiplicative interaction, but additive interaction indicated a non-significant increased risk. For
CV mortality there was no interaction on either scale.
Conclusions: GC use was associated with higher mortality rates in people with comorbid DM compared to people
without DM, despite apparently reassuring similar relative risks. Clinicians need to be aware of the higher baseline
risk in patients with DM, and consider this when prescribing GCs in patients with RA and comorbid DM.
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Rheumatoid arthritis (RA) is an inflammatory disease that
is thought to affect around 1% of the UK population [1]
and is associated with a significantly higher rate of cardio-
vascular (CV) mortality compared to the general popula-
tion [2]. Glucocorticoids (GC) have been widely used as a
treatment for RA since their discovery in the 1950s [3]
and continue to be used in around half of patients with
RA [4]. Although GCs have many benefits, they also have
risks associated with them, including possible increased
risk of CV events and mortality [5, 6]. In addition, GCs
are known to increase the risk of diabetes mellitus (DM)
[7, 8] and are associated with poor glucose control [9],
meaning they may also affect the long-term outcome of
DM (including CV events and mortality) [10, 11]. This has
not been investigated in patients with RA. Further, it is
not known how the additional burden of DM and then
GC therapy influence the cardiovascular and mortality risk
in patients with RA. Therefore an important unanswered
question is whether GC treatment in RA is associated with
worse outcomes in patients with comorbid DM, compared
to patients without DM.
As we think that the baseline risk of CV and all-cause
mortality for patients with RA and DM will be higher
than those with RA only, to investigate the impact of
GCs it is appropriate to look at the absolute risks as well
as the relative risks. The aims of this study were: 1) to
compare the event rates for all-cause mortality and CV
mortality, by GC use status and DM status, and 2) to
examine whether DM modifies, on either the multiplica-
tive or additive scales, the effect of GCs on all-cause
mortality and CV mortality.
Methods
Setting
This was a retrospective cohort study using data from
the Clinical Practice Research Datalink (CPRD) which
was linked to mortality data from the Office of National
Statistics (ONS). The CPRD is a large database of pri-
mary care electronic medical records that covers around
7% of the UK population and has been shown to be
broadly representative of the UK population. Consenting
practices in England have linkage to the ONS mortality
data, which represents around 58% of all CPRD practices
[12]. CPRD provide indicators of when a practice’s data
was up to research standard, and whether a patient’s
data meets their acceptability standards. For this study,
only data from practices that consented to ONS linkage
were used if the data met acceptability standards and
was up to research standard.
Study population
The study period began at the start of ONS coverage (1st
January 1998) and ended 1st October 2011. Patients withincident RA during the study period were identified from
CPRD using a validated algorithm where patients have to
have either at least 2 Read codes for RA and no alternative
diagnosis after their last RA code or a Read code for RA
and at least 2 product (medication) codes for Disease-
Modifying Anti-Rheumatic Drugs (DMARDs) and no al-
ternative diagnosis for the DMARDs in the previous 5
years [13]. Patients entered into the study upon RA diag-
nosis and participation ended at death, the date the
patient left the practice or at the end of the study period.
All patients were registered with the practice for a year
prior to RA diagnosis, to ensure patients were truly inci-
dent cases.Exposures
Patients were identified as having type 2 DM if they had
either (1) a Read code for type 2 DM; (2) at least two pre-
scriptions for oral anti-diabetic medication, either on 2
different dates or the same date with 2 types of medica-
tion; or (3) fasting blood sugar ≥7.0mmol/litre, random
glucose test ≥11.1mmol/litre, glucose tolerance test ≥11.1
mmol/litre or a glycosylated haemoglobin (HbA1C) ≥7%
[7]. Patients with polycystic ovary syndrome (PCOS)
treated with metformin were excluded as it was possible
they were incorrectly identified as diabetic because of
taking anti-diabetic medication. Diagnosis of DM was
time-varying and could be prior to diagnosis of RA
whereby a person would be flagged as diabetic throughout
follow-up, or during follow-up whereby a person would be
flagged as diabetic from the point of DM diagnosis. Where
the diagnosis was made on the basis of two sequential pre-
scriptions, the date of onset was allocated as the date of
the second prescription to avoid immortal time bias.
Oral GC therapy was identified using product codes
from prescription data. Patients were classified by current/
recent use of GCs, whereby a person was classified as
exposed for the duration of each GC prescription and for
6months after the end of the prescription.Outcomes
All-cause and CV mortality were identified through
linkage to ONS data with date of death and cause of
death provided. Cause of death was recorded on ONS
using International Statistical Classification of Diseases
and Related Health Problems (ICD) version 10 codes.
Deaths prior to 2001 were recorded using ICD-9 codes
and these were mapped to ICD-10 codes. There also
were 31 deaths recorded on CPRD but not on ONS
and these were included in the all-cause mortality ana-
lyses. CV mortality was identified using ICD-10 codes
under the circulatory chapter heading as the under-
lying cause of death.
Costello et al. BMC Rheumatology             (2020) 4:4 Page 3 of 8Covariates
Age at RA diagnosis was calculated using year of birth and
year of RA diagnosis. Gender was given on the CPRD
database. Baseline Charlson comorbidity index was deter-
mined using an adaption of the index for CPRD data
where diseases were identified through Read codes for
diagnosis at any point prior to RA diagnosis [14]. DMARD
types and non-steroidal anti-inflammatory drugs
(NSAIDs) were identified using product codes and were
time-varying. GC use in the year preceding baseline was
determined from GC prescriptions prior to baseline. Base-
line smoking category (ever or never) was determined
using Read codes and product codes at any point up to
RA diagnosis, or in the 3months after RA diagnosis. Prior
macrovascular disease was defined as diseases of large
blood vessels including myocardial infarction, stroke,
peripheral artery disease or amputation [15] and were
identified through Read codes prior to RA diagnosis. Body
mass index (BMI) at baseline was calculated using median
height and weight measurements from the 5 years prior to
baseline. All code lists can be found in Additional file 1.
Analysis
For both outcomes, mortality rates were estimated (with
95% confidence intervals (CI)), stratified by time-varying
DM status and time-varying current/recent use of GCs.
As mentioned earlier, the baseline risk of CV and all-
cause mortality for patients with RA and DM will be
higher than those with RA only. Therefore, to investigate
the impact of GCs both rate ratios (RR) and rate differ-
ences (RD) between GC users and non-GC users were
calculated for those with and without DM separately.
When estimating the effect of both GC exposure and
DM status, the presence of interaction was measured on
both the multiplicative scale, corresponding to the RR,
and on the additive scale, corresponding to the RD.
Interaction on the additive scale can give more meaning-
ful comparisons as it is not dependent on baseline risks
[16]. Crude and adjusted Cox proportional hazards (PH)
regression models were fitted with an interaction term
for time-varying DM and time-varying current/recent
use of GCs. Multiplicative interaction was assessed via
the inclusion of an interaction term in the Cox model.
Additive interaction cannot be estimated directly from
the Cox model as it depends on the baseline hazard
function [17]. However, we can estimate the Relative Ex-
cess Risk due to Interaction (RERI) and Ratio of Abso-
lute Effects (RAE): 1) RERI [17, 18] assesses if there is a
difference in the hazard differences. The RERI is equal
to 0 if the additive interaction effect is equal to 0. There-
fore, if it is statistically significantly different from zero
then this is interpreted as a statistically significant differ-
ence in the hazard differences between those with and
without DM, and indicates the direction of the effect. 2)RAE is defined as the ratio of hazard differences in pa-
tients with DM compared to those without DM (See
Additional file 2 for further information). Departure
from 1 indicates a difference in the two groups and it
was calculated here in addition to the RERI as it gives an
indication of the magnitude of the difference in sub-
group absolute effects, unlike the RERI. Both measures
are calculated after the Cox model as a function of the
model parameters.
Missing data
Ever smoking at baseline and baseline BMI had 753 (8%)
and 3849 (42%) missing data, respectively. Multiple im-
putation with 57 imputations was used to replace these
missing values. The number of imputations was based
on the fraction of missing information. Forty-nine pa-
tients did not have a Townsend score, however this was
not imputed as it was not used in the final models.
Results
There were 15,833 patients identified who had a diagnosis
of RA and were registered at their practice for at least 1
year prior to diagnosis, 6748 were excluded due to either
inconsistent follow-up dates, being age 18 years or under
at diagnosis, being registered at a practice that did not
consent to ONS linkage or having a diagnosis of PCOS
and being treated with metformin, resulting in 9085 pa-
tients in the final cohort (Fig. 1). The cohort had a mean
follow-up of 5.2 years (standard deviation 3.5 years).
At baseline there were 1034 patients with DM, and
761 patients developed DM during follow-up. Compared
to those without DM at baseline, those with DM at base-
line were older (DM: mean 64 years vs non-DM: mean
59 years) had a greater proportion of males (DM: 37% vs
non-DM: 30%) and ever smokers (DM: 58% vs non-DM:
50%), had more GC use prior to baseline (DM: 31% vs
non-DM: 23%), had more macrovascular disease at base-
line (DM: 11% vs non-DM: 4%) and had a higher BMI
(DM: 30 vs non-DM: 27) (Table 1). 50% of patients had
used GC at any point during follow-up. Those with prior
DM had slightly higher average GC dose over follow-up
(DM: 4.9 mg prednisolone equivalent dose (PED) vs
non-DM: 4.4 mg PED). Across both those with and with-
out DM those who ever used GC were older and had
more prior macrovascular disease.
All-cause mortality
During follow-up there were 1,005 deaths. Mortality rates
differed according to the presence of DM and the use of
GC therapy. For those with DM, the mortality rate was
67.4 (95% CI 57.1 to 79.5) per 1000 person-years (pyrs)
in those with GC exposure and 22.5 (95% CI 18.7 to
27.1) per 1000 pyrs in those without GC exposure. For
those without DM, the mortality rate was 44.6 (95% CI
Fig. 1 Flowchart of patients selected for the study
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10.2 (95% CI: 9.1 to 11.4) per 1000 pyrs in those without
GC exposure. The risk ratio for GC use was slightly
lower for those with DM (DM RR 2.99 (95% confidence
interval (CI) 2.32 to3.87) compared to those with no
DM RR 4.37 (95% CI 3.77 to 5.07)). However, despite
this lower RR, those with DM had a higher RD com-
pared to those without DM (DM RD: 44.9 (95% CI: 32.9
to 56.8) vs no DM RD: 34.4 (95% CI: 30.1 to 38.7 per
1000 pyrs) (Table 2).
The unadjusted Cox PH model for all-cause mortality
showed current/recent GC use and DM interacted on the
multiplicative scale (0.69 (95% CI 0.51, 0.91)). Adjustment
removed this significant interaction (0.86 (95% CI: 0.64–
1.15)) (Table 3). In both the unadjusted and adjusted
models both the RERI and RAE indicated increased risk
for those with DM and current/recent GC use but were
not statistically significant (adjusted RAE: 1.22 (95% CI:
0.86 to 1.72) (Table 3).
CV mortality
There were 384 CV deaths during follow-up. A similar
pattern was seen for CV mortality, where a slightly lower
RR was seen for those with DM compared to those
without DM, but the RD was higher for those with DM
(Table 2). The unadjusted and adjusted Cox models
showed that DM did not interact with ever GC use on themultiplicative scale, the additive interaction indicated in-
creased risk but was not statistically significant (Table 3).Discussion
In this study, we have shown that in patients with RA and
DM, the RR of GC use on all-cause and CV mortality was
slightly lower than in patients with RA alone. This might
seem reassuring at first glance, suggesting the impact of
GC therapy in patients with DM is no worse than in pa-
tients without DM. However, the RD was notably higher
in those with DM compared to those without. The higher
baseline mortality rate for those with DM is thus resulting
in a greater number of excess deaths despite the slightly
lower RR. When examined together in an adjusted Cox
PH model, current/recent use of GC in those with DM
was associated with a non-significant absolute increased
hazard of all-cause mortality compared to those without
DM, but not a relative increased hazard. A similar pattern
was seen for CV mortality. The increased absolute hazard
for all-cause mortality indicates the greater public health
impact of people with RA using GCs if they have DM.
This increase is not seen on the multiplicative scale be-
cause the comparison made is relative to other patients
with DM who have a higher risk of mortality prior to
using GCs. Notably, most studies only assess effect modifi-
cation or interaction on the multiplicative scale, despite
Table 1 Baseline characteristics by diabetes mellitus status and ever use of glucocorticoids during follow-up (N = 9085)
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Missing 2 (0.2) 1 (0.2) 1 (0.2) 41 (0.5) 20 (0.5) 21 (0.5) 5 (0.7) 1 (0.4) 4 (0.8)
SES quintile at baseline (In subset), n (%)






























839 (20.8) 892 (22.2) 156
(20.5)











Fifth (most deprived) 150
(14.5)
71 (13.9) 79 (15.1) 986 (12.3) 493 (12.3) 493 (12.3) 92 (12.1) 32 (11.9) 60 (12.2)
Missing 2 (0.2) 1 (0.2) 1 (0.2) 41 (0.5) 20 (0.5) 21 (0.5) 6 (0.8) 1 (0.4) 5 (1.0)
Charlson comorbidity index
at baseline, mean (SD)
2.57
(0.8)
2.48 (0.8) 2.66 (0.8) 1.32 (0.7) 1.23 (0.6) 1.42 (0.7) 2.63 (0.8) 2.39
(0.7)
2.76 (0.8)




41 (8.0) 72 (13.8) 297 (3.7) 108 (2.7) 189 (4.7) 77 (10.1) 16 (6.0) 61 (12.4)
History of GC use in year













Duration of diabetes at baseline (yrs)
Mean (SD) 4.59 (3.7) 4.88 (3.8) 4.31 (3.6) N/A N/A N/A N/A N/A N/A














N/A N/A N/A N/A N/A N/A
2 26 (2.5) 8 (1.5) 18 (3.5) N/A N/A N/A N/A N/A N/A
3 1 (0.1) 1 (0.2) 0 (0) N/A N/A N/A N/A N/A N/A




86 (16.8) 69 (13.2) N/A N/A N/A N/A N/A N/A

















Hydroxychloroquine 261 132 129 2304 1129 1175 138 49 (18.2) 89 (18.1)
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Table 1 Baseline characteristics by diabetes mellitus status and ever use of glucocorticoids during follow-up (N = 9085) (Continued)



















N = 1034 N = 512 N = 522 N = 8051 N = 4026 N = 4025 N = 761 N = 269 N = 492

















Leflunomide 75 (7.3) 28 (5.5) 47 (9.0) 719 (8.9) 264 (6.6) 455 (11.3) 57 (7.5) 13 (4.8) 44 (8.9)
Other 70 (6.8) 15 (2.9) 55 (10.5) 549 (6.8) 117 (2.9) 432 (10.7) 54 (7.1) 6 (2.2) 48 (9.8)
Average GC dose during
follow up, mean (SD)
4.93
(14.0)
0 9.8 (18.5) 4.38 (6.3) 0 8.75 (6.4) 5.02 (6.3) 0 7.77 (6.4)
aCharacteristics at time of diabetes mellitus diagnosis
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tive scales [16, 19].
To our knowledge no previous studies have looked at
the effect of both GCs and DM on mortality in patients
with RA. Studies have looked at short term diabetic out-
comes with GC use, investigating its effects on glucose
intolerance or metabolic syndrome in patients with RA
[8, 20]. Two studies have investigated longer term out-
comes of GC use in patients with DM but not RA. One
looked at mortality 14 years after diagnosis and found
that after adjustment for age and gender there was not
increased mortality in patients with DM who had GC
treatment compared to those who did not, however only
small numbers of patients had GC treatment in this
study (35/1334) [10]. The other study aimed to describeTable 2 Mortality rates, rate ratios and rate difference by diabetes mthe adverse effects of GC treatment in patients with DM,
but did not discuss mortality [11]. We and others have
previously shown GC therapy to be associated with
higher all-cause mortality rates in patients with RA.
However, a causal association is difficult to establish as
several biases are at play in an observational study in-
cluding ‘peri-mortal bias’ [21].
This was a large study that used electronic medical re-
cords that are a rich source of medical information.
CPRD data has been shown to be broadly representative
of the UK population, so results should be generalisable
to the UK RA population [12]. However, there are some
limitations with the study. Although we used a validated
algorithm to identify patients with RA there could still
be some misclassification. Further misclassification mayellitus and glucocorticoid use status
Table 3 Multiplicative and additive interactiona between

































a On the multiplicative scale significant interaction is different than 1, on the
additive scale significant interaction for the RERI is different than 0 and for the
RAE is different than 1
bAdjusted for age, gender, Charlson comorbidity index, baseline BMI, baseline
smoking status, DMARDs, prior GC, prior macrovascular disease and NSAIDs
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rather than dispensing data. However, any differences
between prescribed medication and medication dis-
pensed are unlikely to differ by DM status. To allow
examination of interaction a simple model of oral GC
exposure was used, therefore it was not possible to
examine the impact of GC dose or intramuscular GCs.
This study focuses on type 2 DM, as GCs induce insulin
resistance similar to type 2 diabetes. Results are likely to
be similar with type 1 diabetes, but given the different
pathogenetic mechanisms, further work would be re-
quired to confirm this. There could be confounding by
indication, as RA disease severity has been shown to
confound the relationship between GCs and CVD in RA
[22]. However, there is no measure of disease activity
available on CPRD and we would not expect the con-
founding to differentially affect those with or without
DM. There may be known unmeasured confounding,
there were no measures of biologic DMARD use in this
study as biologics are only prescribed in secondary care
in the UK. This may be important as biologics have been
shown to be associated with reduced CVD [23]. Unfor-
tunately we were not able to use methods to explore un-
measured confounding as most are applied to relative
risks rather than additive interaction terms.Conclusions
This study gives an indication that GC therapy may be
associated with a higher number of deaths in patientswith RA and comorbid type 2 DM. Rheumatologists
should consider DM status when prescribing GCs to pa-
tients with RA given this potential impact of GC therapy
on glucose control and mortality.
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